VX-984 (M9831) is primarily investigated for its potential in cancer therapy, particularly as a DNA damage response inhibitor. It is studied for its ability to enhance the efficacy of DNA-damaging agents, such as chemotherapy and radiation, by targeting and inhibiting key DNA repair mechanisms in cancer cells. This approach aims to selectively increase the sensitivity of cancer cells to treatment while minimizing damage to healthy cells. Research focuses on its application in treating solid tumors and hematologic malignancies, where it may improve therapeutic outcomes when used in combination with existing treatments.